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Background
Myocardial fibrosis is a hallmark of hypertrophic cardio-
myopathy (HCM) and may contribute to arrhythmias and
heart failure. Sarcomere mutations appear to induce profi-
brotic changes before left ventricular hypertrophy (LVH)
develops. Measuring T1 relaxation times with contrast
cardiac magnetic resonance (CMR) allows robust quantifi-
cation of the cardiac extracellular volume (ECV) and non-
invasive assessment of diffuse myocardial fibrosis.
Methods
A genotyped HCM population underwent contrast CMR
with measurement of T1. Subjects included sarcomere
mutation carriers with LVH (G+/LVH+, n = 37) and
without LVH (G+/LVH-, n = 30); HCM patients with-
out mutations (sarcomere-negative HCM, n = 11); and
mutation-negative healthy controls (n = 10). Concurrent
echocardiography and serum biomarkers of collagen
synthesis, hemodynamic stress, and myocardial injury
were available in a subset.
Results
Late gadolinium enhancement (LGE) was present in
>60% of overt HCM patients but absent from G+/LVH-
subjects. Compared to controls, ECV was increased in
patients with overt HCM, as well as G+/LVH- mutation
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Table 1 CMR Metrics of Fibrosis and Serum PICP levels
Control N=10 p-value* Control vs
Preclinical
Preclinical HCM
N=30
p-value* Preclinical vs
Overt
Overt HCM
N=37
p-value* Control vs
Overt
ECV (range) 0.26 ± 0.01
(0.24-0.31)
<0.001 0.33 ± 0.01 (0.23-
0.38)
<0.001 0.37 ± 0.01
(0.31-0.51)
<0.001
ECV, excluding LGE 0.26 ± 0.01 <0.001 0.33 ± 0.01 <0.001 0.37 ± 0.01 <0.001
LGE present, %
(#yes / #no)
0% (0/10) 0% (0/29) 78.4% (29/8)
LGE, g 0 0.8 0 0.004 16.7 ± 4.9 0.003
LGE, % LV mass 0 0.7 0 0.0006 7.76 ± 1.96
(0.9-44.6%)
0.001
PICP, μg/L 63.08 ± 4.19 <0.001 83.81 ± 4.39 0.035 108.04 ± 9.81 <0.001
Data are presented as means adjusted for family relations and age ± standard error *p values <0.017 are statistically significant and adjusted for age and family
relations ECV = extracellular volume; LGE = late gadolinium enhancement; PICP = carboxy-terminal propeptide of procollagen type I
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+ / L V H + ,G + / L V H - ,c o n t r o l s ,r e s p e c t i v e l y ,P < 0 . 0 0 1 ) .
ECV was correlated with NT-proBNP levels (r=0.61,
P<0.001) and global E’ velocity (r=-0.48, P<0.001). ECV
and LGE were higher in sarcomeric HCM than sarco-
mere-negative HCM.
Conclusions
Myocardial ECV is increased not only in sarcomere
mutation carriers with overt HCM, but also those with
normal LV wall thickness. These data provide further
evidence that fibrotic remodeling is triggered early in
disease pathogenesis. Assessing ECV may help charac-
terize the development of HCM-induced myocardial
fibrosis, ultimately supporting novel strategies to modify
disease by targeting interstitial fibrosis.
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Figure 1 ECV is significantly increased in HCM sarcomere mutation
carriers both with and without LVH Compared to normal controls,
ECV was 25% in G+/LVH- subjects and 42% higher in G+/LVH+
HCM patients (p<0.001 for all comparisons to controls). ECV was
further increased by 13% in overt HCM compared to G+/LVH-
subjects (p=0.0003).
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